title: Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.
abstract: Onchocerciasis is targeted for elimination in Africa through annual or biannual ivermectin mass drug administration (MDA). An immunodiagnostic test, based on the detection of human IgG4 antibodies in the blood to the Onchocerca volvulus-specific antigen Ov16, is one of the recommended tools for determining whether transmission is interrupted and mass treatment can stop. For different transmission settings, the relationship between post-MDA Ov16 antibody prevalence in children (measured 1 year after the last round of MDA) and the duration and coverage of MDA, the mf prevalence in the population, and the probability that onchocerciasis is eventually eliminated is explored through mathematical modelling.
  
  
  
  The ONCHOSIM model was extended with new output on the Ov16 antibody serostatus of individuals. Seroconversion was assumed to be triggered by the first worm establishing in the host, with seroconversion occurring either before maturation, after maturation or only after the start of mf production. We are mainly interested in seroconversion rates in children, and for now ignore the possibility of seroreversion to simplify the model.
  
  
  
  Yearly repeated MDA leads to a strong reduction in the parasite acquisition rate in humans. This reduces the seroconversion rate in newborns and young children, while those who seroconverted before the start of control remain antibody positive. Both the microfiladermia prevalence in the population aged 5 years and above and the Ov16 antibody prevalence in children under 10 declined with increasing duration of MDA. The association between either of these indicators and the model-predicted probability of elimination was not influenced much by the assumed treatment coverage levels, but was found to depend on baseline endemicity levels, assumptions regarding the trigger of seroconversion, and diagnostic test characteristics (sensitivity and specificity).
  
  
  
  Better understanding of the dynamics of Ov16 antibody responses is required for accurate interpretation of seroprevalence data and more precise estimation of endpoint for MDA. Our study demonstrates that this endpoint will be dependent on baseline endemicity levels, which should be taken into account in guidelines for defining when to stop MDA.
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Yvonne L
authors.initials: YL
authors.lastname: Lont
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Luc E
authors.initials: LE
authors.lastname: Coffeng
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Sake J
authors.initials: SJ
authors.lastname: de Vlas
authors.affiliation: PATH, Seattle, Washington, United States of America.
authors.forename: Allison
authors.initials: A
authors.lastname: Golden
authors.affiliation: PATH, Seattle, Washington, United States of America.
authors.forename: Tala
authors.initials: T
authors.lastname: de Los Santos
authors.affiliation: PATH, Seattle, Washington, United States of America.
authors.forename: Gonzalo J
authors.initials: GJ
authors.lastname: Domingo
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
authors.forename: Wilma A
authors.identifier: 0000-0001-9509-1328
authors.initials: WA
authors.lastname: Stolk
mesh_terms: D000349:Africa / Q000453:epidemiology; D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood*; D003657:Decision Making; D060740:Disease Eradication; D015801:Helminth Proteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008954:Models, Biological; D008962:Models, Theoretical; D017181:Onchocerca volvulus / Q000276:immunology*; D009855:Onchocerciasis / Q000097:blood / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control*; D015995:Prevalence; D016036:Seroepidemiologic Studies
chemical_list: D000909:Antibodies, Helminth; D015801:Helminth Proteins; D007074:Immunoglobulin G